Karihtala P. How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?. AO [Internet]. 2025 Jun. 25 [cited 2026 May 11];64:815-29. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/43645